Investor Action Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 02/03/22
NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market Under Nasdaq RulesPRNewsWire • 02/03/22
Shareholder Action Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 02/02/22
NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq RulesPRNewsWire • 01/31/22
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)Business Wire • 01/27/22
NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron VariantPRNewsWire • 01/27/22
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)Business Wire • 01/26/22
NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron SurgePRNewsWire • 01/26/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) InvestorsBusiness Wire • 01/24/22
Shareholder Alert: Robbins LLP Reminds Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading ShareholdersBusiness Wire • 01/23/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) InvestorsBusiness Wire • 01/21/22
DEADLINE: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPWNewsfile Corp • 01/21/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of InvestorsBusiness Wire • 01/20/22
Shareholder Alert: Robbins LLP Informs Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading ShareholdersBusiness Wire • 01/20/22
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 01/20/22
The Law Offices of Frank R. Cruz Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of InvestorsBusiness Wire • 01/20/22
ALERT: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPWBusiness Wire • 01/20/22
NRX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against NRx Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 01/20/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of InvestorsBusiness Wire • 01/19/22
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against NRx Pharmaceuticals, Inc. (NRXP; NRXPW)Newsfile Corp • 01/19/22
NRXP EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – NRXP; NRXPWBusiness Wire • 01/19/22
NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved TreatmentsBenzinga • 01/18/22
